Presentation is loading. Please wait.

Presentation is loading. Please wait.

ISEE/ISEA Conference, Athens, Greece, September 1999 ARSENIC-CONTAMINATED WELL WATER AND SKIN DISORDERS IN HUHHOT, INNER MONGOLIA (IMCAP) Presented By:

Published byShana Potter Modified over 9 years ago

Similar presentations

Presentation on theme: "ISEE/ISEA Conference, Athens, Greece, September 1999 ARSENIC-CONTAMINATED WELL WATER AND SKIN DISORDERS IN HUHHOT, INNER MONGOLIA (IMCAP) Presented By:"— Presentation transcript:

1 ISEE/ISEA Conference, Athens, Greece, September 1999 ARSENIC-CONTAMINATED WELL WATER AND SKIN DISORDERS IN HUHHOT, INNER MONGOLIA (IMCAP) Presented By: Richard Wilson Harvard University

2 ISEE/ISEA Conference, Athens, Greece, September 1999 Distribution of individuals with Different Exposure/Outcome Status E/O# of SubjAge  SDGender _______Race____________________ Status(N)(years)M (%)F (%)H (%)M (%) _____________________________________________________________________ Known317933  201628 (51)1551(49)3172 (99.8)7 (0.2) Unknown 497  10 22 (45)27 (55)49 (100.0)0 (0.0) Total322832  201650 (51)1578 (49)3221 (99.8)7 (0.2) _____________________________________________________________________

3 ISEE/ISEA Conference, Athens, Greece, September 1999 Demographic distribution in three selected villages # of Subj.Age  SD Gender___ Race____________ Village(N)(years)M (%)F (%)H (%)M (%) ____________________________________________________________________ Hei He175536  19901 (51)854 (49)1748 (99.6)7 (0.4) Tie MG25727  19128 (50)129 (50)257 (100)0 (0.0) Zhi JL1167 30  19599 (51)568 (49)1167 (100)0 (0.0) ____________________________________________________________________

4 ISEE/ISEA Conference, Athens, Greece, September 1999 Distribution of the study population by age groups and by villages Age (yrs)Hei He____Tie Men GengZhi Ji LiangTotal______ n%n%n%n __________________________________________________________________________________________________ <101176.76425.021518.439612.5 10-1932618.63814.819116.455517.5 20-2934619.84919.126222.565720.7 30-3930817.65320.719416.655517.5 40-4925914.8124.7927.936311.4 50-591649.4218.21008.62859.0 60-691307.4114.3786.72196.9 70+1025.883.1353.01454.6 __________________________________________________________________________________________________ Total1752100.0256100.01167100.03175 100.0

5 ISEE/ISEA Conference, Athens, Greece, September 1999 Frequency distribution of wells and statistics of As concentration Frq. by sample #___ Frq. by As concentration grps As concentration statistics (ppb) Village One Two Three<10 10- 50- 150- 500+Mn Std. Min P25 Med P75 Max ______________________________________________________________________________________________________________ Hei He 76 2 1 1 29 46 3 0 65 35 537 57 81 176 Tie MG34 11 08 16 16 4 1 75 106 520 48 80 615 Zhi JL55 5 0 35 13 1 4 7 156 386 5 5 5 27 2000 ______________________________________________________________________________________________________________ Total165 18 144 58 63 11 897 230 514 43 80 2000

6 ISEE/ISEA Conference, Athens, Greece, September 1999 Descriptive statistics of As concentration & cumulative As dosage Exposure N A-Mean A-Std. G-Mean G-Std Min P25 Med P75 Max__ MaxCon 317985.2133.5 50.0 3.0 5.0 30.0 58.0 110.0 2000.0 CumDose 3179 1571.0 1982.1 740.0 4.2 5.0 300.0 948.0 2184.0 20372.0 _____________________________________________________________________________________________________________

7 ISEE/ISEA Conference, Athens, Greece, September 1999 Descriptive statistics for the eight Maximum Arsenic Concentration (MAC) groups (ppb) MAC (ppb)NA-meanA-SDG-MNG-SDMinP25MedP75Max _______________________________________________________________________________________________________________________________________ <102875.00.05.01.055555 10-40514.74.714.11.31013131728 30-41232.83.332.61.13030343449 50-51654.93.154.81.15052565859 60-56570.39.469.71.16062628192 100-536121.718.6120.31.2100105115147147 150-416174.632.8172.51.2156158158182345 500+ 421048.3423.2974.91.558061596111742000 _______________________________________________________________________________________________________________________________________

8 ISEE/ISEA Conference, Athens, Greece, September 1999 Descriptive statistics for the eight Cumulative Arsenic Dose (CAD) groups (ppb-year) CAD NA-meanA-SDG-MNG-SDMinP25MedP75Max __________________________________________________________________________________________________________________________________________ <10 750.05.01.055555 10- 9720.17.218.71.51015202631 32- 18061.820.058.51.43445608098 100- 554202.564.6191.91.4100150196260315 316- 800617.1198.2584.91.4318442590780999 1000- 11231893.0602.81796.61.410001352185623573154 3162- 3804656.51507.54461.91.331633590413052549761 10000+ 3712971.22425.012772.81.21005910955127401491220372 ___________________________________________________________________________________________________________________________________________

9 ISEE/ISEA Conference, Athens, Greece, September 1999 Cumulative % by Max. As Conc. Cumulative Percentage Maximum As Concentration [ppb] <1010-30-50-60-100-150-500+ 0.2.4 6 8 1

10 ISEE/ISEA Conference, Athens, Greece, September 1999 Cumulative % by Cum. As Dosage

11 ISEE/ISEA Conference, Athens, Greece, September 1999 Duration and density of exposure by Maximum As Concentration MAC NExp. Duration (yrs) Exp. Density Cum. Percentage Groups(Mean  Std.)(person-yrs) of Exp Den(%) _____________________________________________________________________________ <1028721  195,8857.4 10-40523  189,23919.0 30-41222  198,96830.3 50-51625  1812,69646.3 60-56528  1915,83666.3 100-53625  1713,64583.4 150-41629  1811,97598.5 500+4228  151,180100.0 ____________________________________________________________________________ Total3,17925  1879,424

12 ISEE/ISEA Conference, Athens, Greece, September 1999 Duration and density of exposure by cumulative As dosage CAD groups NExp. Duration (yrs) Exp. Density Cum. Percentage (Mean  Std.) (person-yrs) of Exp Den (%) ____________________________________________________________________________ <1071  070.0 10-973  23300.4 32-1807  511971.9 100-55415  13830612.4 316-80020  151580632.3 1000-112331  143452375.8 3162-38046  171749697.8 10000+3748  191759100.0 Total317825  1879424

13 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between max. As concentration (ppb) and hyperkeratosis HyperkeratosisCases SubjectsPrev. (%)ExpectedObs/Exp <1012870.3515.50.06 10-14050.2521.90.05 30-44120.9722.30.18 50-85161.5527.90.29 60-235654.0730.60.75 100-6153611.3829.02.10 150-4541610.8222.52.00 500+294269.052.312.76 Total17231795.41172.01.00 Linear trend in proportion:  2 =191, p<0.001

14 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between max. As concentration (ppb) and dyspigmentation Dyspigmentation CasesSubjectsPrev. (%)ExpectedObs/Exp <1032871.0510.90.27 10-04050.0015.40.00 30-44120.9715.70.26 50-75161.3619.60.36 60-115651.9521.50.51 100-425367.8420.42.06 150-344168.1715.82.15 500+204247.621.612.51 Total12131793.81121.01.00 Linear trend in proportion:  2 =123, p<0.001

15 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between max. As concentration (ppb) and Kerato-Dyspigm Kerato+DyspigmCasesSubjectsPrev. (%)ExpectedObs/Exp <1012870.35.490.12 10-04050.0011.980.00 30-34120.7312.180.25 50-65161.1615.260.39 60-115651.9516.710.66 100-315365.7815.851.96 150-244165.7712.301.95 500+184242.861.2414.49 Total9431792.9694.001.00 Linear trend in proportion:  2 =101, p<0.001

16 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between max. As concentration (ppb) and Skin Cancer Skin CancerCasesSubjects Prev. (%)ExpectedObs/Exp <1002870.000.720.00 10-04050.001.020.00 30-04120.001.040.00 50-05160.001.300.00 60-05650.001.420.00 100-05360.001.350.00 150-54161.201.054.78 500+3427.140.1128.38 Total831790.258.001.00 Linear trend in proportion:  2 =21, p<0.001

17 ISEE/ISEA Conference, Athens, Greece, September 1999 Prevalence of Four Outcomes by Max. As Concentration

18 ISEE/ISEA Conference, Athens, Greece, September 1999 Obs/Exp Ratio by Max. As Concentration Observed/Expected Ratio Maximum As Concentration [ppb] 0 10 20 30 Skin Cancer Keratosis+Dyspigmentation Dyspigmentation Keratosis <10 10- 30- 50- 60- 100- 150- 500+

19 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between cum. As dosage (ppb-years) and hyperkeratosis HyperkerotosisCases SubjectsPrev. (%)ExpectedObs/Exp <10070.000.40.00 10-0970.005.20.00 32-01800.009.70.00 100-25540.3630.00.07 316-128001.5043.30.28 1000-7711236.8660.81.27 3162-6438016.8420.63.11 10000+173745.952.08.49 Total17231785.41172.01.00 Linear trend in proportion:  2 =175, p<0.001

20 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between cum. As dosage (ppb-years) and Dyspigmentation DyspigmentationCases SubjectsPrev. (%)ExpectedObs/Exp <10070.000.30.00 10-0970.003.70.00 32-11800.566.90.15 100-25540.3621.10.09 316-78000.8830.50.23 1000-5611234.9942.81.31 3162-4338011.3214.52.97 10000+123732.431.48.52 Total12131783.81121.01.00 Linear trend in proportion:  2 =114, p<0.001

21 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between cum. As dosage (ppb-years) and Kerato-Dyspigm Kerato+DyspigmCases SubjectsPrev. (%)ExpectedObs/Exp <10070.000.20.00 10-0970.002.90.00 32-01800.005.30.00 100-15540.1816.40.06 316-58000.6323.70.21 1000-4411233.9233.21.32 3162-353809.2111.23.11 10000+93724.321.18.22 Total9431782.9694.01.00 Linear trend in proportion:  2 =95, p<0.001

22 ISEE/ISEA Conference, Athens, Greece, September 1999 Relationship between cum. As dosage (ppb-years) and Skin Cancer Skin CancerCases SubjectsPrev. (%)ExpectedObs/Exp <10070.000.00.00 10-0970.000.20.00 32-01800.000.50.00 100-05540.001.40.00 316-08000.002.00.00 1000-411230.362.81.41 3162-33800.791.03.14 10000+1372.700.110.74 Total831780.258.01.00 Linear trend in proportion:  2 =10, p<0.002

23 ISEE/ISEA Conference, Athens, Greece, September 1999 Prevalence of the four skin disorders by cum. As dosage Prevalence [%] Cumulative As Dosage [ppb_years] 0 20 40 60 Skin Cancer Kerotosis+Dyspigmentation Dyspigmentation Kerotoses <10 10- 32- 100- 316- 1000- 3162- 10000+

24 ISEE/ISEA Conference, Athens, Greece, September 1999 Obs/Exp Ratio by Cum. As Dosage Observed/Expected Ratio Cumulative As Dosage [ppb_years] 0 2 4 6 8 10 Skin Cancer Kerotosis+Dyspigmentation Dyspigmentation Kerotoses <10 10- 32- 100- 316- 1000- 3162- 10000+

25 ISEE/ISEA Conference, Athens, Greece, September 1999 Prevalence (%) of skin disorders adjusted by age and sex for MAC measure Maximum As Concentration Groups (ppb) ____________________________________________________________________________ Skin Disorders <1010-30-50-60-100-150-500+ ______________________________________________________________________________________________________ Hyperkeratosis 0.40.31.01.63.511.09.471.9 Dyspigmentation 1.10.01.11.41.67.87.053.7 Kerato+Dyspig 0.40.00.81.21.65.84.848.1 Skin Cancer 0.00.00.00.00.00.01.05.9

26 ISEE/ISEA Conference, Athens, Greece, September 1999 Prevalence (%) of skin disorders adjusted by age and sex for CAD measure Cumulative As Dosage Groups (ppb-years) _____________________________________________________________________________________ Skin Disorders <1010-30-50-60-100-150-500+ _____________________________________________________________________________________ Hyperkeratosis0.00.00.00.42.05.822.554.2 Dyspigmentation0.00.00.50.41.24.316.053.3 Kerato+Dyspig0.00.00.00.21.03.014.239.1 Skin Cancer0.00.00.00.00.00.30.22.0

27 ISEE/ISEA Conference, Athens, Greece, September 1999 Age-Sex Adjusted Prevalence by Max. As Concentration Age-sex Standardized Prevalence [%] Maximum As Concentration [ppb] 0 20 40 60 80 Skin Cancer Keratosis+Dyspigmentation Dyspigmentation Keratosis <10 10- 30- 50- 60- 100- 150- 500+

28 ISEE/ISEA Conference, Athens, Greece, September 1999 Age-Sex Adjusted Prevalence by Cum. As Dosage Observed/Expected Ratio Cumulative As Dosage [ppb_years] 0 2 4 6 8 10 Skin Cancer Kerotosis+Dyspigmentation Dyspigmentation Kerotoses <10 10- 32- 100- 316- 1000- 3162- 10000+

29 ISEE/ISEA Conference, Athens, Greece, September 1999 Eight skin cancer cases and their demographic and exposure characteristics Date of Case#HholdAgeSexRaceOccupOnsetDiagWell MACDur CAD ______________________________________________________________________________________________________________________________________________ 1GLJ65MHanFarmer19801996101022061540 9624 2GLW58MHanFarmer19851998101022061537 2195 3ZHL59FHanFarmer19721992101022061552 12858 4LYZ71FHanFarmer19851994114070217651 4147 5MJX44MHanFarmer19861996114070217643 2692 6ZM62MHanFarmer19851992114070217660 6191 7MHK71MHanFarmer19871998114070515857 2827 8WER59FHanFarmer19871994114070515836 1299

30 ISEE/ISEA Conference, Athens, Greece, September 1999 Age-Sex Adjusted Prevalence by Cum. As Dosage Age-Sex Standardized Prevalence [%] Cumulative As Dosage [ppb_years] 0 20 40 60 Skin Cancer Kerotosis+Dyspigmentation Dyspigmentation Kerotosis <10 10- 32- 100- 316- 1000- 3162- 10000+

31 ISEE/ISEA Conference, Athens, Greece, September 1999 The Inner Mongolia Collaborative Project was started in 1994 to help them understand, analyze, and extend their data and bring them to public attention. Hohhot Sanitation and Anti-Epidemic Station Dr. Luo Zhengdong, Dr Zhang Yu-Min and other collaborators. Institute of Environmental Health and Engineering, Chinese Academy of Preventive Medicine in Beijing Dr. He Xingzhouu Consultants in Epidemiology and Occupational Health (CEOH) in Washington, D.C., Dr. Steven Lamm University of Texas, Austin, Dr Steven Tucker, Dr. Lai Shenghan Medical School, University of Miami, Dr. Dan Byrd Harvard University, Dr. Richard Wilson

Download ppt "ISEE/ISEA Conference, Athens, Greece, September 1999 ARSENIC-CONTAMINATED WELL WATER AND SKIN DISORDERS IN HUHHOT, INNER MONGOLIA (IMCAP) Presented By:"

Similar presentations

Measures of Disease Frequency

Measures of Disease Frequency
M2 Medical Epidemiology

M2 Medical Epidemiology
The Early Release Program of the National Health Interview Survey Jeannine Schiller, M.P.H., Jane F. Gentleman, Ph.D., Eve Powell-Griner, Ph.D. National.

The Early Release Program of the National Health Interview Survey Jeannine Schiller, M.P.H., Jane F. Gentleman, Ph.D., Eve Powell-Griner, Ph.D. National.
UNIVERSITY OF CAMBRIDGE

UNIVERSITY OF CAMBRIDGE
The epidemiological tool-box A ssociations – quantification using rate ratios, rate differences, odds ratios.

The epidemiological tool-box A ssociations – quantification using rate ratios, rate differences, odds ratios.
《 Promotion of Capability and Effectiveness for Tobacco Control Program among Rural Residents* 》 --Report On The Baseline Survey (Tobacco use status among.

《 Promotion of Capability and Effectiveness for Tobacco Control Program among Rural Residents* 》 --Report On The Baseline Survey (Tobacco use status among.
Environmental Perchlorate Exposure and Human Health: from Newborn to Cancer.

Environmental Perchlorate Exposure and Human Health: from Newborn to Cancer.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.

1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
CEEH workshop February 2008 The importance of demographic changes Henrik Brønnum-Hansen University of Southern Denmark.

CEEH workshop February 2008 The importance of demographic changes Henrik Brønnum-Hansen University of Southern Denmark.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.

1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
Descriptive Research in Physical Activity Epidemiology Descriptive Research in Physical Activity Epidemiology CHAPTER 1 CHAPTER 11.

Descriptive Research in Physical Activity Epidemiology Descriptive Research in Physical Activity Epidemiology CHAPTER 1 CHAPTER 11.
1997 Summer Public Health Research Institute on Minority Health, UNC-CH Living Beyond Our “Means”: New Methods for Comparing Distributions Camara Phyllis.

1997 Summer Public Health Research Institute on Minority Health, UNC-CH Living Beyond Our “Means”: New Methods for Comparing Distributions Camara Phyllis.
Body Weight and Mortality: New Population Based Evidences Body Weight and Mortality: New Population Based Evidences Dongfeng Gu, MD Dongfeng Gu, MD Fu.

Body Weight and Mortality: New Population Based Evidences Body Weight and Mortality: New Population Based Evidences Dongfeng Gu, MD Dongfeng Gu, MD Fu.
Measuring Epidemiologic Outcomes

Measuring Epidemiologic Outcomes
Groundwater Arsenic Concentrations and Cancer Incidence Rates: A Regional Comparison in Oregon Harmony Fleming, MS Anna K Harding, PhD Department of Public.

Groundwater Arsenic Concentrations and Cancer Incidence Rates: A Regional Comparison in Oregon Harmony Fleming, MS Anna K Harding, PhD Department of Public.
Biology in Focus, HSC Course Glenda Childrawi, Margaret Robson and Stephanie Hollis A Search For Better Health Topic 11: Epidemiology.

Biology in Focus, HSC Course Glenda Childrawi, Margaret Robson and Stephanie Hollis A Search For Better Health Topic 11: Epidemiology.
Demography and Aging. What is “demography”? Demography is the study of populations Counting and describing people Age, sex, income, marital status… Demographers.

Demography and Aging. What is “demography”? Demography is the study of populations Counting and describing people Age, sex, income, marital status… Demographers.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,

® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
Descriptive Epidemiology

Descriptive Epidemiology
Study Design and Analysis in Epidemiology: Where does modeling fit? Meaningful Modeling of Epidemiologic Data, 2010 AIMS, Muizenberg, South Africa Steve.

Study Design and Analysis in Epidemiology: Where does modeling fit? Meaningful Modeling of Epidemiologic Data, 2010 AIMS, Muizenberg, South Africa Steve.

Similar presentations

Ads by Google